(Q40222496)

English

Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study

scientific article published on 29 January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

Alan J. Thompson

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

ORCID Public Data File 2021

author name string

W Rashid

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

G R Davies

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

D T Chard

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

C M Griffin

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

D R Altmann

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

D H Miller

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

178-185

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APCs in Theiler's virus-infected mice

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070758

21 January 2018

Identifiers

10.1177/1352458506070758

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40222496&oldid=1889343740"